Synjardy XR 25 mg/1

Synjardy XR 25 mg/1 is an extended-release tablet combining empagliflozin and metformin hydrochloride. It is designed to help manage type 2 diabetes by improving blood sugar control. This medication is suitable for adults and is available in a 90-tablet bottle.

Synjardy XR 25 mg/1 is primarily used to improve glycemic control in adults with type 2 diabetes. The combination of empagliflozin and metformin hydrochloride works to lower blood sugar levels. This medication is often prescribed as part of a comprehensive treatment plan that includes diet and exercise. It is important to consult with a healthcare provider to determine if Synjardy XR 25 mg/1 is appropriate for your specific needs.

Common effects of Synjardy XR 25 mg/1 may include gastrointestinal discomfort, such as nausea, diarrhea, or vomiting. Some individuals may also experience urinary tract infections or hypoglycemia, especially when combined with other diabetes medications. It is important to monitor blood sugar levels regularly and report any severe or persistent side effects to a healthcare provider.

Synjardy XR 25 mg/1 should be taken exactly as prescribed by a healthcare provider. It is important to follow the dosage instructions carefully and not to crush or chew the extended-release tablets. This medication should be stored at room temperature and kept out of reach of children. Individuals with certain medical conditions, such as kidney or liver disease, should discuss potential risks with their healthcare provider before starting this medication.

Synjardy XR 25 mg/1 may interact with other medications, including certain antibiotics, diuretics, and other diabetes drugs. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be limited, as it can increase the risk of lactic acidosis. Always consult with a healthcare provider before starting or stopping any medication.